FDA Expands Remicade Approval for Psoriatic Arthritis Treatment

HORSHAM, Pa. - Centocor Inc. recently announced that the FDA has expanded marketing approval for Remicade (infliximab) for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis, in addition to reducing signs and symptoms of active arthritis.

The Aug. 14 approval was based on data from two double-blind, placebo-controlled clinical studies that found psoriatic arthritis patients treated with Remicade had less structural damage and were more than twice as likely to achieve clinically meaningful improvement in physical function compared with patients receiving placebo.

Psoriatic arthritis is an immune-mediated inflammatory disease affecting approximately one million men …